-
Spurs closing in on Man City's Marmoush after signing Savio
-
Man City sign Lille's Bouaddi for 100 mn euros
-
Celtic count the cost of Champions League flop
-
Sooriyabandara, Mendis lead Sri Lanka fightback after follow-on
-
Lebanon accuses Israel of burning forest, farmland in south
-
With ropes and chants, thousands move Japanese castle
-
Nepal floods at China border kill 8, cause 'major casualties' in Tibet
-
Zurich Diamond League: five events to watch
-
France eases cow diets as cheesemakers sweat
-
'Black smoke' chokes Pakistan maternity ward as hospital fire kills 14 infants
-
America unites in mourning for Dolly Parton
-
French flight attendant wins landmark breast cancer ruling
-
Meta and US states discuss settlement in landmark social media trial: report
-
Sri Lanka 83-2 after India enforce follow-on in second Test
-
Fire haze threatens health of millions in Indonesia, ministry warns
-
Pakistan hospital fire kills 14 infants
-
Senegal-made sickle cell treatment raises hopes, reduces costs
-
Iceland to vote on resuming EU talks in close referendum
-
Iran says Hormuz strait still closed despite transit corridor talks
-
North Korea to 'bring joy' to Kim with 100 athletes at Asian Games
-
'Our patron saint': Tennesseans mourn local hero Dolly Parton
-
US LGBTQ community mourns 'diva' Dolly Parton
-
Australian police hunt thieves in $250,000 oyster heist
-
England bid to banish booze woes as Pakistan seek self-respect
-
Coordinated attacks: Thailand's southern insurgency flares
-
High quality, low risk: record number of Japanese in Premier League
-
Asian Games chiefs hold talks as participant numbers balloon
-
Stocks edge higher as oil drops on fresh Mideast hopes
-
Too small for fries: drought shrinks Belgian potatoes
-
Pakistan's girls fight for their place in the boxing ring
-
Drought-hit Danube gives way to fossil hunt in Bulgaria
-
Five things to know about Anthropic ahead of Wall Street debut
-
Julia Curlee, CIA officer fired by White House for being transgender
-
Social media use on the rise among Australian under-16s after ban: data
-
Fave or flop? A guide to gauging video game success
-
EON Resources Inc. Announces 92 Horizontal Well Drilling Program Has Begun! $1 Million Per Month Increase Anticipated in Free Cash Flow in Q4 2026
-
Who is the Best Eyelid Surgeon in Kirkland?
-
Who Does the Best Plastic Surgery in Florida?
-
How to Manage Costs for Urgent Plumbing Repairs
-
How to Fix DIY Home Improvement Regrets Months Later
-
Eagle Plains Reports Anomalous Radioactivity from First Drillholes at the Don Lake Uranium Project, Saskatchewan
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - August 26
-
Instagram chief admits touting teen safety tool while omitting it was barely used
-
Williams-Alcaraz fall in US Open mixed quarter-finals
-
'Final Fantasy', 'The Witcher' in spotlight at Europe gaming bash
-
Mark Carney, the former central banker who said 'no' to Trump
-
Syrian Kurdish leader dissolves force that spearheaded jihadist fight
-
Segner out of South Africa tour as New Zealand injuries pile up
-
Trump raises prospect of demolishing iconic Kennedy Center
-
Meta knew teen safety tools were ineffective, witnesses testify
New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms
NEW YORK CITY, NY / ACCESS Newswire / April 7, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX), a precision-guided biotech and life sciences company advancing innovative therapeutic platforms, has entered into a 12-part, one-year strategic media agreement with New to The Street to expand its national and international visibility across television, digital, and outdoor platforms.
The campaign will highlight Medicus Pharma's differentiated pipeline, including SkinJect™, a localized immuno-oncology platform targeting non-melanoma skin cancers such as basal cell carcinoma and rare conditions like Gorlin Syndrome, representing a multi-billion-dollar market opportunity. The series will also feature Teverelix®, a next-generation GnRH antagonist designed for patients with advanced prostate cancer and acute urinary retention associated with enlarged prostate conditions-addressing a significant and growing global market.
Under the agreement, New to The Street will produce and distribute a comprehensive media campaign designed to elevate Medicus Pharma's corporate narrative, clinical progress, and long-term growth strategy to a broad investor audience.
The series will include 12 in-depth executive interviews released monthly, with each segment broadcast across Bloomberg Television in the United States, reaching approximately 124 million households, and additional features airing on FOX Business Network as sponsored programming.
"Our platform is built to provide public companies with consistent, high-impact visibility across television, digital, and outdoor media," said Vince Caruso, Co-Founder of New to The Street. "Medicus Pharma's innovative therapeutic platforms, particularly SkinJect™ and Teverelix®, represent meaningful advancements in high-demand clinical areas, and we are excited to support their continued growth and investor awareness."
As part of the integrated campaign, Medicus Pharma will benefit from extensive commercial and digital exposure, including 80 monthly television commercial placements in the New York market during peak trading hours, as well as national ad distribution across Bloomberg Television and FOX Business Network.
The agreement also includes premium outdoor advertising in New York City, featuring high-frequency digital billboard placements across iconic 42nd Street displays and Times Square, ensuring consistent brand visibility in one of the world's most recognized financial and media corridors.
Digital amplification will extend across New to The Street's media ecosystem, including its flagship YouTube channel with over 4.45 million subscribers and its NewsOut platform, bringing the combined subscriber reach to more than 5.1 million. The campaign will also include 24 press releases over the course of the year, coordinated social media distribution, and inclusion in targeted investor email newsletters.
Additional components of the program include quarterly accredited investor events at Hudson Yards in New York City, offering direct engagement with high-net-worth investors and financial professionals, as well as feature coverage in Wall Street New York Magazine, distributed in both print and digital formats to over 31,000 subscribers.
Medicus Pharma will retain full licensing rights to all produced television, billboard, and digital media assets generated throughout the campaign.
The engagement will be supported by ongoing strategic coordination, including weekly planning calls and monthly content optimization initiatives, including Connected TV (CTV) and short-form video distribution.
About Medicus Pharma Ltd. (NASDAQ:MDCX)
Medicus Pharma Ltd. is a precision-guided biotech and life sciences company focused on accelerating the clinical development of innovative therapeutic assets. Its pipeline includes SkinJect™, a localized immuno-oncology platform targeting non-melanoma skin cancers, and Teverelix®, a next-generation GnRH antagonist for prostate-related conditions and advanced prostate cancer. The Company operates globally across multiple clinical programs addressing significant unmet medical needs.
About New to The Street
New to The Street is one of the longest-running U.S. and international sponsored television brands, broadcasting weekly as sponsored programming on Bloomberg Television and FOX Business Network. For over 17 years, the platform has provided public and private companies with long-form interviews, national television distribution, earned media coverage, and iconic outdoor advertising across New York City. New to The Street also operates one of the largest business-focused YouTube channels, reaching millions of subscribers globally. New to The Street T.V. https://youtube.com/@newtothestreettv?si=SxYTGE7JpfzvTk5y
Media Contact:
Monica Brennan
Communications Lead
[email protected]
SOURCE: New to The Street
View the original press release on ACCESS Newswire
M.King--AT